Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: Insights from the INTERACT trial

American Heart Journal

Volumn 149, Issue 4 SUPPL., 2005, Pages

  Goodman, Shaun ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NON ST ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REGISTER; REVIEW;

EID: 17444403236     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.02.022     Document Type: Article

References (26)

1. E.M. Antman Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 94 1996 911 921
2. C.B. Granger, J. Hirsch, and R.M. Califf Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial Circulation 93 1996 870 878
3. S.G. Goodman, D. Fitchett, and P.W. Armstrong Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Circulation 107 2003 238 244
4. S.S. Anand, S. Yusuf, and J. Pogue Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin Circulation 107 2003 2884 2888
5. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N Engl J Med 337 1997 447 452
6. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601
7. E.M. Antman, M. Cohen, and D. Radley Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis Circulation 100 1999 1602 1608
8. E.M. Antman, M. Cohen, and C. McCabe Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J 23 2002 308 314
9. K.A. Fox, E.M. Antman, and M. Cohen Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention Am J Cardiol 90 2002 477 482
10. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
11. M. Cohen, P. Theroux, and S. Borzak Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin Am Heart J 144 2002 470 477
12. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
13. The GUSTO investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
14. M.E. Bertrand, M.L. Simoons, and K.A. Fox Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 23 2002 1809 1840
15. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) Available at: http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm 2002
16. M.A. Blazing, J.A. de Lemos, and H.D. White Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial JAMA 292 2004 55 64
17. The SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
18. J.A. De Lemos, M.A. Blazing, and H.D. White Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin, and an early conservation initial management strategy: Results from the A phase of the A-to-Z Trial Eur Heart J 25 2004 1694 1699
19. K.A. Fox, P.A. Poole-Wilson, and R.A. Henderson Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina Lancet 360 2002 743 751
20. The GRACE Investigators Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes Am Heart J 141 2001 190 199
21. K.A. Fox, S.G. Goodman, and W. Klein Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 23 2002 1177 1189
22. A. Budaj, D. Brieger, and P.G. Steg Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE) Am Heart J 146 2003 999 1006
23. W. Klein, W. Kraxner, and R. Hodl Patterns of use of heparins in ACS. Correlates and hospital outcomes: The Global Registry of Acute Coronary Events (GRACE) Thromb Haemost 90 2003 519 527
24. J.W. Hoekstra, C.V. Pollack, and M.T. Roe Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative Acad Emerg Med 9 2002 1146 1155
25. M.T. Roe, E.M. Ohman, and C.V. Pollack Changing the model of care for patients with acute coronary syndromes-implementing practice guidelines and altering physician behavior Am Heart J 146 2003 605 612
26. K.P. Singh, M.T. Roe, and A. Chen Improved outcomes with low-molecular-weight heparin versus unfractionated heparin for patients receiving glycoprotein IIb/IIIa antagonists for acute coronary syndromes: Results from the CRUSADE initiative Circulation 108 2003 IV 579